Skip to main content

Scientists uncover “evolutionary arms race” between cancer and immune system

Vancouver – A new study by BC Cancer scientists has uncovered the tricks used by the deadliest ovarian cancer to escape the immune system.
Use this image as both the current Page Image and for News listings

This sets the stage for a better understanding of how and why patients respond to promising new immunotherapies.  

Immunotherapy stimulates the patient's own immune system to recognize and destroy tumour cells. It is yielding remarkable outcomes for cancer patients to date and is by far one of the most exciting and active areas of modern cancer care and research.

The study published today in the scientific journal Cell used advanced molecular and computational techniques to analyze how tumour cells in patients with high-grade serous ovarian cancer (HGSC) — the most common and lethal subtype of epithelial ovarian cancers —escape attack from immune cells.

"Our findings reveal fundamentally new insights into the cause and consequences of ovarian cancer and immune cell interaction," said Dr. Sohrab Shah, a senior scientist at BC Cancer, a UBC associate professor and senior author of the study. "The results provide a new lens through which we can interpret a host of recently launched ovarian cancer immunotherapy clinical trials around the world.

The team of interdisciplinary researchers used advanced molecular measurements and computer algorithms to analyze how immune cells (aka, white blood cells) infiltrate tumours. They "zoomed in" to get a better look at the spaces between the immune and cancer cells to see the proteins present on their surfaces. And they sequenced DNA to understand genetic changes that took place within cancer cells after interacting with immune cells.

"Our findings reveal an evolutionary arms race between immune cells and HGSC cells," said Allen Zhang, a UBC MD/PhD student at BC Cancer and the lead author on the study. "As the immune system mounts an attack on a tumour, some cancer cells are eliminated while others evolve and change to resist attack from immune cells. This may help us understand why HGSC often responds poorly to current immunotherapies."

Killer T cells are a subtype of immune cell that have the powerful ability to target and destroy infected or cancerous cells. In this study, scientists noticed that a strong Killer T cell infiltration of ovarian tumours was associated with less diversity among the types of cancer cells present in the tumour. This indicated that Killer T cells had successfully tracked and eliminated many of the tumour cells as they evolved but they weren't able to kill them all, prompting the scientists to take a closer look at the cells that managed to escape.

They identified combinations of genetic changes that help HGSC cells escape attack from Killer T cells and they plan to use this knowledge in the development of more powerful experimental immunotherapies, including T cell therapy, for gynecological cancers. T cell therapy involves extracting the patient's own T cells, conditioning or engineering them to recognize and kill cancer cells and infusing large numbers of those programmed cells back into the patient's body.

"We've known for several years that many ovarian cancer patients launch a strong immune response against their tumours, yet this response often fails to control tumour growth over the long-term," said Dr. Brad Nelson, a distinguished scientist at BC Cancer and co-senior author of the study. "This study has revealed the different tricks used by HGSC tumours to escape from the immune system, leading to exciting new ideas for engineering more potent immune responses that can overcome these various escape mechanisms."

Inspired by success in treating other cancers especially in most types of advanced leukemia, BC Cancer's Immunotherapy Team, led by Drs. Brad Nelson and Rob Holt, is ready to launch the first of a series of clinical trials for ovarian and other gynecological cancers.  

The study was funded by the BC Cancer Foundation, Canadian Cancer Society Research Institute, Canada's Networks of Centres of Excellence, Canadian Institutes of Health Research, Terry Fox Research Institute, Cancer Research Society, Genome Canada and Genome British Columbia, Canada Research Chairs Program, Michael Smith Foundation for Health Research, CANARIE Foundation and a Vanier Canada Graduate Scholarship.

Partner Institutions include BC Cancer, University of British Columbia, BC Children's Hospital Research Institute, University of Victoria, Ludwig Institute for Cancer Research – University of Oxford, Vancouver General Hospital and The Institute of Cancer Research.

The study, Interfaces of malignant and immunologic clonal dynamics in ovarian cancer, is available from Cell, here: https://www.cell.com/cell/abstract/S0092-8674(18)30445-8

Facts

  • More than 300 women are diagnosed with ovarian cancer each year in British Columbia.
  • Approximately 250 women in the province die from ovarian cancer each year.
  • HGSC is the most malignant form of ovarian cancer and accounts for up to 70 per cent of all ovarian cancer cases.
  •  80 per cent of women diagnosed with HGSC relapse despite an initial response to treatment.

BC Cancer, part of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visit www.bccancer.bc.ca or follow us on Twitter @BCCancer.

The BC Cancer Foundation is the fundraising partner of BC Cancer. Together with our donors we are changing the outcome for people affected by cancer in B.C. and beyond by connecting personalized care, innovative research and opportunities to contribute. We are the largest funder of cancer in B.C. and every dollar raised stays right here at BC Cancer to advance research, enhance care and break down cancer to benefit the people of B.C.

The Provincial Health Services Authority (PHSA) plans, manages and evaluates selected specialty and province-wide health care services across BC, working with the five geographic health authorities to deliver province-wide solutions that improve the health of British Columbians. For more information, visit www.phsa.ca or follow us on Twitter @PHSAofBC.

-30-

For more information or to arrange an interview, please contact:

Kevin Sauve
Communications Officer, BC Cancer
Provincial Health Services Authority
Email: media@bccancer.bc.ca
PHSA media line: 778-867-7472

 
 
SOURCE: Scientists uncover “evolutionary arms race” between cancer and immune system ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority